Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

A Study of the Pharmacokinetics of Atazanavir (ATV)/Ritonavir(RTV) Administered as Part of Highly Active Antiretroviral Therapy (HAART) in HIV-1 Infected Pregnant Women

To determine what dosing regimen of atazanavir (ATV) / ritonavir (RTV) produces adequate drug exposure during pregnancy compared to drug exposure in historical data in human immunodeficiency virus (HIV) infected participants.

Inclusion Criteria:

• HIV-infected pregnant women
• > 18 years of age
• Between week 12 and 32 gestation
• CD4 > 200 cells/mm³
• Treatment-naive with HIV RNA > 400 c/mL, on HAART with HIV RNA <50 c/mL, or previously treated with ATV (< 3 weeks) with HIV RNA>400 c/mL